Business
Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer
Findings from prospective, population-based study presented at ESMO Breast Cancer Congress 2023 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc.
About this update from Veracyte, Inc.
[{"type":"text","content":"\nFindings from prospective, population-based study presented at ESMO Breast Cancer Congress 2023\n\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nVeracyte, Inc. (Nasdaq: VCYT) announced that new data show the use of the Prosigna Breast Cancer Assay altered treatment decisions for patients with early-stage breast cancer, including significantly reducing the use of chemotherapy among those with clinically high-risk disease. The findings are from EMIT, a prospective, multi-year, population-based study in Norway that is investigating the impact of molecular testing – specifically, the Prosigna test – on breast cancer care and outcomes. These initial data focused on treatment decisions and were shared in a poster (#103P) today at ESMO Breast Cancer Congress 2023, taking place May 11-13 in Berlin.\n\n\n“Our findings demonstrate the important role that gene expression testing, and in particular the Prosigna assay, can play in offering physicians better prognostic information to help guide next steps for their patients with breast cancer,” said Bjørn Naume, M.D., Professor at the Department of Oncology, Rikshospitalet Oslo University Hospital. “Specifically, Prosigna test results changed physicians’ treatment decisions in all patient clinical-risk groups with early breast cancer, regardless of whether they were low-, intermediate-, or high-risk, and reduced treatment discrepancies across hospitals.”\n\n\nFor the study, researchers evaluated data for 2,164 women in Norway with early-stage (node-negative) breast cancer, recording physicians’ treatment decisions for these patients before and after a Prosigna test result. Prior to Prosigna results, physicians directed 27% to no systemic treatment (low-risk patients), 38% to endocrine therapy only (intermediate-risk patients) and 35% to chemotherapy followed by endocrine therapy (high-risk patients). After Prosigna test results, these treatment decisions changed to 25%, 51% and 24%, respectively. The researchers found that use of Prosigna changed adjuvant therapy decisions for almost one-third (29%) of patients. Notably, for patients assigned to chemotherapy prior to Prosigna results, 45% were de-escalated to endocrine therapy following Prosigna results.\n\n\nThe Prosigna assay analyzes the activity of the PAM50 gene signature, along with clinical-pathological features, to provide a ho...